Effects of cognitive-behavioral therapy on neurotrophic factors in patients with major depressive disorder

Silva, Sally K. da; Wiener, Carolina David; Ghisleni, Gabriele; Oses, Jean Pierre; Jansen, Karen; Molina, Mariane Lopez; Silva, Ricardo; Souza, Luciano D.M.

doi:10.1590/1516-4446-2017-2357

Cited by 9 publications

(7 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In line with the three other studies on the role of BDNF in psychotherapy for depression (Bakker et al, 2014;da Silva et al, 2018;Koch et al, 2009;Rayner et al, 2019), our findings suggested that BDNF levels on average do not play a role in the effects of psychotherapy for depression. Our findings contrast the other studies that found a relation between response to CBT and BDNF (Fullana et al, 2012;Kobayashi et al, 2005) in the treatment of anxiety disorders.…”

Section: Discussionsupporting

confidence: 92%

“…A strength of the present study was the relatively large sample size compared to earlier studies (da Silva et al, 2018;Kobayashi et al, 2005;Koch et al, 2009). In addition, because of the large variation in participating treatment centers and inclusion of many therapists with varying educational backgrounds, external validity is considered high (Bruijniks et al, 2020).…”

Section: Discussionmentioning

confidence: 95%

“…However, not all studies reported significant associations between serum BDNF and treatment outcomes. da Silva et al (2018) showed that serum levels of BDNF measured in blood did not change after 16 weekly sessions of CBT for depression, while in another study BDNF measured in plasma did not predict response to 12 to 16 sessions of twice weekly IPT for depression (Koch et al, 2009). Also, the Val66Met polymorphism was not related to response in CBT for anxiety disorders (Santacana et al, 2016) or in a genome-wide meta-analysis of psychological treatment outcome for depression or anxiety (Rayner et al, 2019).…”

Section: Introductionmentioning

confidence: 95%

See 2 more Smart Citations

Working memory moderates the relation between the brain-derived neurotropic factor (BDNF) and psychotherapy outcome for depression

Bruijniks

Grootheest

Cuijpers

et al. 2020

Journal of Psychiatric Research

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 95%

Section: Introductionmentioning

confidence: 95%

See 1 more Smart Citation

Working memory moderates the relation between the brain-derived neurotropic factor (BDNF) and psychotherapy outcome for depression

Bruijniks

Grootheest

Cuijpers

et al. 2020

Journal of Psychiatric Research

View full text Add to dashboard Cite

show abstract

“…neuron depolarization (Aloe et al, 2002;Lessmann et al, 2003;Castrén, 2004). It is believed that an imbalance of pro-BDNF and mature BDNF can cause neuronal degeneration and behavioral impairment (Cuello et al, 2010;Rosso et al, 2017).…”

Section: Bdnf Functionmentioning

confidence: 99%

Blood Brain-Derived Neurotrophic Factor (BDNF) and Major Depression: Do We Have a Translational Perspective?

Arosio

Guerini

Voshaar

et al. 2021

Front. Behav. Neurosci.

View full text Add to dashboard Cite

Major depressive disorder (MDD) affects millions of people worldwide and is a leading cause of disability. Several theories have been proposed to explain its pathological mechanisms, and the “neurotrophin hypothesis of depression” involves one of the most relevant pathways. Brain-derived neurotrophic factor (BDNF) is an important neurotrophin, and it has been extensively investigated in both experimental models and clinical studies of MDD. Robust empirical findings have indicated an association between increased BDNF gene expression and peripheral concentration with improved neuronal plasticity and neurogenesis. Additionally, several studies have indicated the blunt expression of BDNF in carriers of the Val66Met gene polymorphism and lower blood BDNF (serum or plasma) levels in depressed individuals. Clinical trials have yielded mixed results with different treatment options, peripheral blood BDNF measurement techniques, and time of observation. Previous meta-analyses of MDD treatment have indicated that antidepressants and electroconvulsive therapy showed higher levels of blood BDNF after treatment but not with physical exercise, psychotherapy, or direct current stimulation. Moreover, the rapid-acting antidepressant ketamine has presented an early increase in blood BDNF concentration. Although evidence has pointed to increased levels of BDNF after antidepressant therapy, several factors, such as heterogeneous results, low sample size, publication bias, and different BDNF measurements (serum or plasma), pose a challenge in the interpretation of the relation between peripheral blood BDNF and MDD. These potential gaps in the literature have not been properly addressed in previous narrative reviews. In this review, current evidence regarding BDNF function, genetics and epigenetics, expression, and results from clinical trials is summarized, putting the literature into a translational perspective on MDD. In general, blood BDNF cannot be recommended for use as a biomarker in clinical practice. Moreover, future studies should expand the evidence with larger samples, use the serum or serum: whole blood concentration of BDNF as a more accurate measure of peripheral BDNF, and compare its change upon different treatment modalities of MDD.

show abstract

“…Finally, regarding VNS and IPT, few studies have been performed to date. Consequently, the molecular effects of these two important non-pharmacological treatments for MDD patients remain unknown [195][196][197].…”

Section: Molecular Mechanisms Of Non-pharmacological Treatments For Mddmentioning

confidence: 99%

Blues in the Brain and Beyond: Molecular Bases of Major Depressive Disorder and Relative Pharmacological and Non-Pharmacological Treatments

Maffioletti

Minelli

Tardito

et al. 2020

Genes

View full text Add to dashboard Cite

Despite the extensive research conducted in recent decades, the molecular mechanisms underlying major depressive disorder (MDD) and relative evidence-based treatments remain unclear. Various hypotheses have been successively proposed, involving different biological systems. This narrative review aims to critically illustrate the main pathogenic hypotheses of MDD, ranging from the historical ones based on the monoaminergic and neurotrophic theories, through the subsequent neurodevelopmental, glutamatergic, GABAergic, inflammatory/immune and endocrine explanations, until the most recent evidence postulating a role for fatty acids and the gut microbiota. Moreover, the molecular effects of established both pharmacological and non-pharmacological approaches for MDD are also reviewed. Overall, the existing literature indicates that the molecular mechanisms described in the context of these different hypotheses, rather than representing alternative ones to each other, are likely to contribute together, often with reciprocal interactions, to the development of MDD and to the effectiveness of treatments, and points at the need for further research efforts in this field.

show abstract

Effects of cognitive-behavioral therapy on neurotrophic factors in patients with major depressive disorder

Abstract: BDNF, beta-NGF, and GDNF were not influenced by the effects of CBT on depressive symptoms.

Cited by 9 publications

References 20 publications

Working memory moderates the relation between the brain-derived neurotropic factor (BDNF) and psychotherapy outcome for depression

Working memory moderates the relation between the brain-derived neurotropic factor (BDNF) and psychotherapy outcome for depression

Blood Brain-Derived Neurotrophic Factor (BDNF) and Major Depression: Do We Have a Translational Perspective?

Blues in the Brain and Beyond: Molecular Bases of Major Depressive Disorder and Relative Pharmacological and Non-Pharmacological Treatments

Contact Info

Product

Resources

About